Company Announcement no. 6/2024 (July 17, 2024)
Inside information
BIRKERØD, DENMARK - ViroGates A/S ("ViroGates" or the "Company"), a medical technology company developing blood tests for better triaging in hospitals to improve patient care and measure levels of chronic inflammation in health clinics, announces its revised financial guidance for 2024.
ViroGates expects full-year revenue between DKK 4.5 and 6 million in 2024 (previously DKK 8 to 10 million) and an EBIT of DKK -14 to -15.5 million in 2024 (previously DKK -10 to -12 million). ViroGates continues to struggle to get uptake in the hospital segment despite established customer interest in the new applications of suPARnostic® products. ViroGates' more recent entry into the longevity and general health management segment has established new customers, however the revenue per customer is still marginal.
Jakob Knudsen, CEO of ViroGates, says: "Despite many good activities and positive feedback in new customer segments, we are disappointed with our achievements in the first half of 2024. We have revamped all forecasting on a customer-by-customer level and concluded that we will not be able to achieve the guided revenue for 2024. We are taking measures to direct all sales activity to segments and customers with the highest possible short-term revenue value and are firmly committed to getting back on a positive trajectory."
For further information, please contact:
ViroGates A/S:
CEO, Jakob Knudsen
Tel. (+45) 2226 1355, email: jk@virogates.com
Certified Advisor:
Västra Hamnen Corporate Finance
Per Lönn
Tel. (+46) 40 200 250, email: ca@vhcorp.se
About ViroGates
ViroGates A/S is an international medical technology company developing and marketing blood test products under the suPARnostic® brand for better triaging in hospitals to improve patient care, reduce healthcare costs and empower clinical staff.
The company was founded in 2000. Headquartered in Denmark, ViroGates' sales force covers Spain, France, and Benelux, while distributors serve other markets. ViroGates' shares (VIRO) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit www.virogates.com.
